Literature DB >> 23275141

High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma.

Yang Lv1, Wei Wang, Wei-Dong Jia, Qi-Kai Sun, Jian-Sheng Li, Jin-Liang Ma, Wen-Bin Liu, Hang-Cheng Zhou, Yong-Sheng Ge, Ji-Hai Yu, Hong-Hai Xia, Ge-Liang Xu.   

Abstract

Periostin (PN) is a kind of secreted glycoprotein, which is closely related to the metastatic potential and prognosis of many kinds of tumors in recent studies. However, the expression level of PN in hepatocellular carcinoma (HCC) and its correlation with tumor angiogenesis and prognosis remain unclear. Here Immunohistochemistry assay was used to determine the expression of PN in HCC and corresponding adjacent tissues from 71 patients. VEGF and CD34 were only examined in HCC tissues of patients mentioned above. Immunohistochemically, the expression of PN in HCC was judged to be positive in 73.2 % (52/71) compared with 19.7 % (14/71) in corresponding adjacent tissues, and it was associated with tumor nodules (P = 0.070), microvascular invasion (P = 0.013), Edmondson grade (P = 0.003), tumor capsula (P = 0.038) and TNM stage (P = 0.000); besides, tumors with PN-positive group expressed higher VEGF (82.7 vs. 26.3 %, χ (2) = 20.195, P = 0.000) and had higher MVD (80.5 ± 36.5 vs. 24.0 ± 19.9, t = -6.395, P = 0.000) than those in PN-negative group. Kaplan-Meier method was used for survival analysis, and Cox regression model was performed for multivariate survival analysis. In particular, the expression of PN was found to be an independent factor for predicting overall and disease-free survival of HCC. It is possible that the expression level of PN in HCC is associated with tumor metastatic potential and angiogenesis. Its abnormal expression could be a predictive factor to anticipate HCC patient's prognosis after surgery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23275141     DOI: 10.1007/s12032-012-0385-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas.

Authors:  Marc-Oliver Riener; Florian R Fritzsche; Christopher Soll; Bernhard C Pestalozzi; Nicole Probst-Hensch; Pierre-Alain Clavien; Wolfram Jochum; Alex Soltermann; Holger Moch; Glen Kristiansen
Journal:  Histopathology       Date:  2010-04       Impact factor: 5.087

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.

Authors:  P Baril; R Gangeswaran; P C Mahon; K Caulee; H M Kocher; T Harada; M Zhu; H Kalthoff; T Crnogorac-Jurcevic; N R Lemoine
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

4.  Differential expression of osteoblast-specific factor 2 and polymeric immunoglobulin receptor genes in nasopharyngeal carcinoma.

Authors:  Yao Chang; Tso-Ching Lee; Jian-Chiuan Li; Ting-Lung Lai; Huey-Huey Chua; Chi-Long Chen; Shin-Lian Doong; Chen-Kung Chou; Tzung-Shiahn Sheen; Ching-Hwa Tsai
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

5.  Differential gene expression between normal and tumor-derived ovarian epithelial cells.

Authors:  R S Ismail; R L Baldwin; J Fang; D Browning; B Y Karlan; J C Gasson; D D Chang
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

6.  Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer.

Authors:  Yasusei Kudo; Ikuko Ogawa; Shojiro Kitajima; Masae Kitagawa; Hidehiko Kawai; Patrick M Gaffney; Mutsumi Miyauchi; Takashi Takata
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

7.  Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.

Authors:  Lindsay Gillan; Daniela Matei; David A Fishman; C S Gerbin; Beth Y Karlan; David D Chang
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

8.  Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells.

Authors:  Atsushi Kanno; Kennichi Satoh; Atsushi Masamune; Morihisa Hirota; Kenji Kimura; Jun Umino; Shin Hamada; Akihiko Satoh; Shinichi Egawa; Fuyuhiko Motoi; Michiaki Unno; Tooru Shimosegawa
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

9.  Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I.

Authors:  S Takeshita; R Kikuno; K Tezuka; E Amann
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

10.  Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway.

Authors:  Shideng Bao; Gaoliang Ouyang; Xuefang Bai; Zhi Huang; Chaoyu Ma; Ming Liu; Rong Shao; Ryan M Anderson; Jeremy N Rich; Xiao-Fan Wang
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

View more
  24 in total

1.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

2.  Periostin promotes liver fibrogenesis by activating lysyl oxidase in hepatic stellate cells.

Authors:  Pradeep Kumar; Tekla Smith; Reben Raeman; Daniel M Chopyk; Hannah Brink; Yunshan Liu; Todd Sulchek; Frank A Anania
Journal:  J Biol Chem       Date:  2018-06-25       Impact factor: 5.157

Review 3.  Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.

Authors:  Alphonse E Sirica; Jorge A Almenara; Chao Li
Journal:  Exp Mol Pathol       Date:  2014-10-28       Impact factor: 3.362

4.  Overexpression of periostin is significantly correlated to the tumor angiogenesis and poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Wei Wang; Qi-Kai Sun; Yi-Fu He; Dong-Chun Ma; Ming-Ran Xie; Chu-Shu Ji; Bing Hu
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

5.  High-level expression of HOXB13 is closely associated with tumor angiogenesis and poor prognosis of hepatocellular carcinoma.

Authors:  Jian-Yu Zhu; Qi-Kai Sun; Wei Wang; Wei-Dong Jia
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

6.  High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.

Authors:  Fei Hu; Xi-Fu Shang; Wei Wang; Wei Jiang; Ce Fang; Dong Tan; Hang-Cheng Zhou
Journal:  Int J Exp Pathol       Date:  2016-03-30       Impact factor: 1.925

7.  Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFκB Signaling in Hepatocellular Carcinoma.

Authors:  Julia C Engelmann; Thomas Amann; Birgitta Ott-Rötzer; Margit Nützel; Yvonne Reinders; Jörg Reinders; Wolfgang E Thasler; Theresa Kristl; Andreas Teufel; Christian G Huber; Peter J Oefner; Rainer Spang; Claus Hellerbrand
Journal:  PLoS Comput Biol       Date:  2015-05-28       Impact factor: 4.475

8.  Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection.

Authors:  Xinhui Huang; Yongyi Zeng; Xiaohua Xing; Jinhua Zeng; Yunzhen Gao; Zhixiong Cai; Bo Xu; Xiaolong Liu; Aimin Huang; Jingfeng Liu
Journal:  Proteome Sci       Date:  2014-05-01       Impact factor: 2.480

9.  Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin.

Authors:  Anke H Hautmann; Josef Schroeder; Peter Wild; Matthias G Hautmann; Elisabeth Huber; Patrick Hoffstetter; Martin Fleck; Christiane Girlich
Journal:  Case Rep Endocrinol       Date:  2014-08-24

10.  High expression of periostin is dramatically associated with metastatic potential and poor prognosis of patients with osteosarcoma.

Authors:  Fei Hu; Wei Wang; Hang-Cheng Zhou; Xi-Fu Shang
Journal:  World J Surg Oncol       Date:  2014-09-15       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.